Premium
Beclomethasone dipropionate aerosol in treatment of perennial and seasonal rhinitis: a review of five years' experience.
Author(s) -
Brown HM,
Storey G,
Jackson FA
Publication year - 1977
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1977.tb04522.x
Subject(s) - medicine , asthma , allergy , respiratory tract , dermatology , corticosteroid , upper respiratory tract infection , nasal discharge , nasal allergy , anesthesia , surgery , respiratory system , immunology
1. Five years' experience in the use of beclomethasone dipropionate aerosol (BDA) in the treatment of 315 patients with upper respiratory tract allergy is reviewed. 2. A total of 223 patients with perennial rhinitis was treated. In 23, where the nasal allergy had recurred after oral corticosteroid therapy for asthma was withdrawn, BDA was effective in 69% of cases. A similar success rate (68%) was recorded in 169 patients suffering from perennial allergic rhinitis alone, but a satisfactory response was observed in only 45% of 31 patients with nasal polypi. 3. In 92 patients with seasonal allergic rhinitis freedom from symptoms was achieved in 80%. 4. A total of approximately 534 patient‐years of treatment has been recorded without any evidence of side‐effects either clinically or on nasal biopsy.